veterans with type 2 diabetes found that GLP-1s were associated with lower risk of developing substance use disorders (SUDs) involving alcohol, cannabis, cocaine, nicotine or opioids
Desbree, A., Houdon, L., Touati, G., Djemili, S., Choker, G., and Flodrops, H
In autoimmune diseases, amino acid metabolism-targeted interventions place greater emphasis on reducing pathological inflammation and promoting tissue repair, and therefore the available evidence is better organized from the perspective of feasible strategies and safety boundaries
GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity
Earlier studies suggested that up to 40% of weight lost on GLP-1 therapy could come from lean mass
FGF-21 Analogues As mentioned above, FGF-21 has many beneficial effects, but the main limitation is the short circulating half-life (30 minutes to 2 hours)